FDA Clearance Tracker · P170019-S036
FoundationOne CDx (F1CDx)
Last checked: Nov 20, 2026Latest source record: Sep 18, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2023
Approved
Time to decision
413 days
Received Aug 1, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170019-S036
- Device name
- FoundationOne CDx (F1CDx)
- Applicant
- Foundation Medicine, Inc.
- Applicant location
- Boston, MA
- Received
- Aug 1, 2022
- Decided
- Sep 18, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P170019
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for a DNA/RNA CoExtraction (CoEx) method, and removal of reporting of copy number alterations (amplifications and deletions/losses) for the tumor profiling indication from the intended use/indications for use when using the DNA/RNA CoEx method.
Source documents
Other decisions for Foundation Medicine, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- FoundationOne CDx (F1CDx)PMA supplement
P170019-S060 · Decided May 27, 2026 · 614 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.